Central and Peripheral Endocannabinoids and Cognate Acylethanolamides in Humans: Association with Race, Adiposity, and Energy Expenditure
Open Access
- 1 March 2011
- journal article
- other
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 96 (3), 787-791
- https://doi.org/10.1210/jc.2010-2028
Abstract
Context: Peripheral and central endocannabinoids and cognate acylethanolamides (AEs) may play important but distinct roles in regulating energy balance. Objective: We hypothesized that in humans central/peripheral endocannabinoids are differently associated with adiposity and energy expenditure and differ by race. Design: We examined associations of arachindonoylethanolamide, 2-arachidonoylglycerol, palmitoylethanolamide, and oleoylethanolamide (OEA) assayed in plasma and cerebrospinal fluid (CSF) with race, adiposity, and energy expenditure. Setting/Participants: In this monitored clinical inpatient study, CSF was obtained by lumbar puncture in 27 individuals (12 Caucasian, 11 American Indian, and four African-American). Twenty-four hour and sleep energy expenditure were measured by indirect calorimetry in a respiratory chamber. Main Outcome Measure: Samples were analyzed from a previous study originally designed to test a blood-brain barrier leptin transport deficit in human obesity. Results: CSF (but not peripheral) 2-arachidonoylglycerol was significantly increased in American Indians compared with Caucasians (18.48 ± 6.17 vs. 10.62 ± 4.58 pmol/ml, P < 0.01). In the whole group, peripheral AEs were positively but in CSF negatively associated with adiposity. However, in multivariate models adjusted for the other peripheral and CSF AEs, peripheral arachindonoylethanolamide was the only AE significantly associated with adiposity. Interestingly, CSF OEA concentrations were positively associated with adjusted 24 hour and sleep energy expenditure (r = 0.47, P < 0.05; r = 0.42, P < 0.05), but peripheral OEA was not. Conclusions: These data indicate a central alteration of the endocannabinoid system in American Indians and furthermore show that AEs in both compartments play an important but distinct role in human energy balance regulation.Keywords
This publication has 20 references indexed in Scilit:
- Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesityJCI Insight, 2010
- Differential alterations of the concentrations of endocannabinoids and related lipids in the subcutaneous adipose tissue of obese diabetic patientsLipids in Health and Disease, 2010
- Circulating Endocannabinoids and N-acyl-ethanolamides in Patients with Sleep Apnea – Specific Role of OleoylethanolamideExperimental and Clinical Endocrinology & Diabetes, 2010
- Basal and Fasting/Refeeding‐regulated Tissue Levels of Endogenous PPAR‐α Ligands in Zucker RatsObesity, 2010
- Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjectsActa Endocrinologica, 2009
- Peripheral endocannabinoid dysregulation in obesity: relation to intestinal motility and energy processing induced by food deprivation and re‐feedingBritish Journal of Pharmacology, 2009
- Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-αNature, 2003
- Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2003
- Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2‐arachidonoyl glycerolBritish Journal of Pharmacology, 2002
- Leptin-regulated endocannabinoids are involved in maintaining food intakeNature, 2001